A 3rd coronavirus vaccine works


Great news out of Business Insider as Lydia Ramsey reports on a 3rd player in the Coronavirus-19 vaccine race that is showing promising results on its testing:

Another Monday, another batch of vaccine results. This time: AstraZeneca and the University of Oxford shared that their coronavirus vaccine was 70% effective on average. That comes on the heels of Pfizer and its partner BioNTech and Moderna both sharing last week that their coronavirus vaccines were 95% and 94.5% effective, respectively.

Moncef Slaoui, the scientific head of Operation Warp Speed, is anticipating things will move quickly from here. He said on Sunday that he expects Americans will starting getting Pfizer’s vaccine as early as December 11, assuming regulators sign off on it.

People in the US could start getting Moderna’s vaccine about a week later, he said, assuming regulators green light that shot as well. Slaoui said he expects Moderna to file for emergency use authorization by the end of November.

Meanwhile — the experimental antibody drug that President Donald Trump took as part of his COVID-19 treatment has received emergency use authorization, a step that could make it more widely available as cases continue to surge. 

Also today in healthcare news: The inside story of how the sprint for a coronavirus vaccine transformed Modernahow coronavirus vaccine development compares to other vaccines in history, and Morgan Stanley predicts it’ll take 4-9 months to vaccinate the majority of the US.

How the sprint for a coronavirus vaccine transformed Moderna into a $39 Billion powerhouse that’s poised to reshape biotech:

  • Moderna went from a hot biotech startup to one of the world’s best-known companies, boosted most recently by its coronavirus-vaccine program.
  • It says its shot is 94.5% effective at protecting people against COVID-19.
  • While those results have yet to be published in a journal and regulators still need to review the data, the scientific feat outlines an exit plan from this pandemic.
  • This is the inside story of how Moderna leveraged its speedy technology platform and ongoing research projects with the National Institutes of Health to develop an effective vaccine in record time.
  • Now valued at $39 billion, the Massachusetts biotech is at the forefront of a revolution in vaccine research, driven by its promising technology.
  • 11/23/2020
  • Lydia Ramsey